Literature DB >> 24529419

Neuropathology of type 2 diabetes: a short review on insulin-related mechanisms.

Elizabeth Guerrero-Berroa1, James Schmeidler2, Michal Schnaider Beeri3.   

Abstract

Postmortem studies have shown that cerebrovascular disease (CVD) neuropathology occurs frequently in type 2 diabetes (T2D) through mechanisms associated with chronic hyperglycemia such as advanced glycation end-products (AGEs). The involvement of T2D in Alzheimer׳s disease (AD)-type neuropathology has been more controversial. While postmortem data from animal studies have supported the involvement of T2D in AD-type neuropathology through insulin mechanism that may affect the development of neuritic plaques and neurofibrillary tangles (NFTs), findings from postmortem studies in humans, of the association of T2D with AD, have been mainly negative. To complicate matters, medications to treat T2D have been implicated in reduced AD-type neuropathology. In this review we summarize the literature on animal and human postmortem studies of T2D neuropathology, mainly the mechanisms involved in hyperglycemia-related CVD neuropathology and hyperinsulinemia-related AD-type neuropathology.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Alzheimer׳s disease; Cerebrovascular disease; Neuropathology; Review; Type 2 diabetes

Mesh：

Substances：

Year:  2014        PMID： 24529419      PMCID： PMC4116474          DOI： 10.1016/j.euroneuro.2014.01.019

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN： 0924-977X            Impact factor:   4.600


  57 in total

Review 1.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

2.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Authors:  Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

3.  Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study.

Authors:  J Heitner; D Dickson
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

4.  Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.

Authors:  Saul Genuth; Wanjie Sun; Patricia Cleary; David R Sell; William Dahms; John Malone; William Sivitz; Vincent M Monnier
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

5.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

6.  A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model.

Authors:  Giselle P Lim; Frédéric Calon; Takashi Morihara; Fusheng Yang; Bruce Teter; Oliver Ubeda; Norman Salem; Sally A Frautschy; Greg M Cole
Journal:  J Neurosci       Date:  2005-03-23       Impact factor: 6.167

7.  Diabetes is related to cerebral infarction but not to AD pathology in older persons.

Authors:  Z Arvanitakis; J A Schneider; R S Wilson; Y Li; S E Arnold; Z Wang; D A Bennett
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

8.  Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus.

Authors:  A W van Deutekom; H W M Niessen; C G Schalkwijk; R J Heine; S Simsek
Journal:  Eur J Endocrinol       Date:  2008-05       Impact factor: 6.664

9.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

Authors:  Wesley Farris; Stefan Mansourian; Yang Chang; Loren Lindsley; Elizabeth A Eckman; Matthew P Frosch; Christopher B Eckman; Rudolph E Tanzi; Dennis J Selkoe; Suzanne Guenette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-12       Impact factor: 11.205

Review 10.  A look inside the diabetic brain: Contributors to diabetes-induced brain aging.

Authors:  Shayna A Wrighten; Gerardo G Piroli; Claudia A Grillo; Lawrence P Reagan
Journal:  Biochim Biophys Acta       Date:  2008-11-05
View more
  4 in total

Review 1.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

2.  Depressive Symptoms Are Associated with Cognitive Function in the Elderly with Type 2 Diabetes.

Authors:  Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; James Schmeidler; Anthony Heymann; Laili Soleimani; Mary Sano; Derek Leroith; Rachel Preiss; Ruth Zukran; Jeremy M Silverman; Michal Schnaider Beeri
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Alzheimer's Disease Polygenic Risk Score Is Not Associated With Cognitive Decline Among Older Adults With Type 2 Diabetes.

Authors:  Sigalit B Manzali; Eric Yu; Ramit Ravona-Springer; Abigail Livny; Sapir Golan; Yuxia Ouyang; Orit Lesman-Segev; Lang Liu; Ithamar Ganmore; Anna Alkelai; Ziv Gan-Or; Hung-Mo Lin; Anthony Heymann; Michal Schnaider Beeri; Lior Greenbaum
Journal:  Front Aging Neurosci       Date:  2022-08-30       Impact factor: 5.702

4.  Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers.

Authors:  Shijia Liu; Peidong Chen; Yang Zhao; Guoliang Dai; Bingting Sun; Yao Wang; Anwei Ding; Wenzheng Ju
Journal:  BMC Pharmacol Toxicol       Date:  2017-07-04       Impact factor: 2.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.